Titration News and Research

RSS

GLP-1 drugs have benefits beyond weight loss. Could microdoses preserve them?

A narrative review suggests GLP-1-based therapies deliver metabolic, cardiovascular, renal, and other systemic benefits, raising interest in whether lower fractional doses could improve tolerability and treatment continuity. However, direct evidence for GLP-1 microdosing remains extremely limited, and researchers say prospective studies are needed to determine whether lower doses preserve long-term benefits.

1 Sep 2026

Intensive blood pressure control lowers stroke recurrence risk in ICH survivors

Intensive, long-term blood pressure-lowering treatment reduced the risk of recurrent stroke by 38%, without increasing serious adverse events, in people who have survived an intracerebral hemorrhage (ICH).

12 Aug 2026

Automated oxygen delivery system improves precision for hospitalized patients

A University of Colorado Anschutz-led clinical trial has found an automated oxygen delivery system helped hospitalized patients spend significantly more time in their target oxygen range compared with standard care, while also reducing exposure to both low and high oxygen levels.

3 Aug 2026

Review outlines effective approaches to reduce recurrent hepatic encephalopathy

Hepatic encephalopathy (HE) is a neurologic complication of advanced liver disease, causing impaired functioning, reduced quality of life (QOL), and increased hospitalisation and mortality.

31 Jul 2026

Hydrogen-powered shipping could deliver $284 billion in annual health benefits

Researchers modeled how replacing conventional global shipping fuels with hydrogen could change PM2.5 and ozone pollution, premature mortality, and monetized health benefits. Under complete transition, the model estimated 129,458 fewer premature deaths and US$284 billion in annual monetized health benefits, although some regions experienced increased pollution from hydrogen production or altered ozone chemistry.

31 Jul 2026

Low-dose lithium may protect brain networks in early Alzheimer’s disease

This perspective examines whether restoring physiological lithium levels could help protect cognition in early Alzheimer’s disease. It proposes that lithium may support cholinergic signaling and brain connectivity, but emphasizes that rigorous, safety-monitored clinical trials are needed.

21 Jul 2026

Dexamphetamine and methylphenidate work similarly for ADHD but differ in weight effects

A head-to-head trial of ADHD treatments finds dexamphetamine and methylphenidate equally effective, with notable differences in weight management over time.

17 Jul 2026

New consensus outlines best practices for obesity medications

Obesity and dietitian societies have joined forces to issue a new consensus statement on recommendations surrounding use of obesity drugs for weight loss treatment.

8 Jul 2026

Semaglutide approval drove a surge in GLP-1 poison center exposures

Following semaglutide's approval, poison center reports of GLP-1 RA exposures doubled, revealing critical trends in patient safety and healthcare utilization.

26 Jun 2026

Bogotá’s strictest COVID restrictions delivered the clearest air-quality gains

A natural quasi-experiment in Suba, Bogotá, found that more stringent COVID-19 mobility restrictions were associated with larger reductions in PM₁₀ and PM₂.₅ air pollution. The findings suggest targeted traffic and emissions controls could improve urban air quality, although ozone responses were more complex, and the results may not generalize beyond this high-traffic district.

21 Jun 2026

Oral GLP-1 drug elecoglipron helps adults lose up to 11.8% body weight

Once-daily oral elecoglipron produced dose-dependent weight loss in adults with obesity or overweight without diabetes, with mean reductions reaching 10.5% at 26 weeks and 11.8% at 36 weeks in the highest-dose weekly-titration group. The phase 2 trial found no evidence of a weight-loss plateau by 36 weeks, while gastrointestinal adverse events were common but generally manageable.

11 Jun 2026

Obesity drug mazdutide reduces weight and waist size in major trial

Once-weekly 9 mg mazdutide produced clinically meaningful weight loss in Chinese adults with obesity, reducing body weight by 16.65% after 60 weeks versus 1.50% with placebo. The phase 3 GLORY-2 trial also found improvements in waist circumference, systolic blood pressure, and lipid markers, but gastrointestinal adverse events were common.

9 Jun 2026

Continuing gout therapy during remission lowers future flare risk

The European Alliance of Associations for Rheumatology - held its 2026 annual Congress in London, where gout was high on the agenda.

3 Jun 2026

Structural insights reveal unique bacterial β-1,2-glucan transport system

Even though sugars are often framed as simple sources of energy, they also serve as structurally complex and functionally diverse molecules that mediate interactions between organisms.

29 May 2026

Study links pediatric sedation strategies with later neurocognitive outcomes

A new Penn Nursing study suggests that the specific sedatives used during critical illness in early childhood may have long-term implications for a child's neurocognitive development.

19 May 2026

Study finds nutritional risks in users of GLP-1 drugs

Adults with overweight or obesity taking the new generation of weight loss drugs semaglutide and tirzepatide tend to eat significantly less, leaving them vulnerable to nutritional deficiencies, according to one of the first real-world studies to examine dietary behavior in people using glucagon-like peptide-1 receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) dual agonists RAs (collectively referred to as GLP-1 RAs) with the help of an AI-powered nutritional tracking app.

9 Apr 2026

Semaglutide for weight loss was linked to a sharp drop in alcohol use in this case report

A 2026 case report describes a 34-year-old man with obesity and alcohol use disorder whose semaglutide treatment for weight loss was associated with a marked drop in drinking over 10 months, with his AUDIT score falling from 27 to 7 and alcohol use dropping from about 15 drinks per week to half a beer per month. The authors frame this as a promising but preliminary finding that adds to growing evidence on GLP-1 drugs and alcohol use, while also stressing that this was a single case and that better AUD screening in family medicine remains important.

2 Apr 2026

Algorithm-guided insulin dosing improves blood sugar control in type 2 diabetes

A University of Virginia Center for Diabetes Technology-developed algorithm – paired with a continuous glucose monitor – can help users better manage their type 2 diabetes by recommending insulin-dose adjustments, a new study found.

24 Mar 2026

Japanese study evaluates sleep architecture and safety of common insomnia drugs

OSA is a common sleep disorder characterized by oxygen desaturation due to repeated airway collapse during sleep.

12 Mar 2026

Combined GLP-1 and GLP-2 treatment appears safe but does not beat placebo for obesity

In a 12-week randomized phase IIa trial in adults with obesity, the dual GLP-1/GLP-2 receptor agonist dapiglutide was well tolerated but did not achieve statistically significant weight loss compared with placebo at 4 mg or 6 mg doses. Although the higher dose showed modest within-group weight reduction and improved HbA1c, unexpectedly substantial placebo-associated weight loss limited the observed treatment effect.

24 Feb 2026